Department of Physical Therapy, School of Health and Human Sciences, Indiana University, Indianapolis, Indiana, USA.
Division of Nephrology and Hypertension, Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA.
Am J Nephrol. 2024;55(3):369-379. doi: 10.1159/000537827. Epub 2024 Feb 20.
Chronic kidney disease (CKD) negatively affects musculoskeletal health, leading to reduced mobility, and quality of life. In healthy populations, carnitine supplementation and aerobic exercise have been reported to improve musculoskeletal health. However, there are inconclusive results regarding their effectiveness and safety in CKD. We hypothesized that carnitine supplementation and individualized treadmill exercise would improve musculoskeletal health in CKD.
We used a spontaneously progressive CKD rat model (Cy/+ rat) (n = 11-12/gr): (1) Cy/+ (CKD-Ctrl), (2) CKD-carnitine (CKD-Carn), and (3) CKD-treadmill (CKD-TM). Carnitine (250 mg/kg) was injected daily for 10 weeks. Rats in the treadmill group ran 4 days/week on a 5° incline for 10 weeks progressing from 30 min/day for week one to 40 min/day for week two to 50 min/day for the remaining 8 weeks. At 32 weeks of age, we assessed overall cardiopulmonary fitness, muscle function, bone histology and architecture, and kidney function. Data were analyzed by one-way ANOVA with Tukey's multiple comparisons tests.
Moderate to severe CKD was confirmed by biochemistries for blood urea nitrogen (mean 43 ± 5 mg/dL CKD-Ctrl), phosphorus (mean 8 ± 1 mg/dL CKD-Ctrl), parathyroid hormone (PTH; mean 625 ± 185 pg/mL CKD-Ctrl), and serum creatinine (mean 1.1 ± 0.2 mg/mL CKD-Ctrl). Carnitine worsened phosphorous (mean 11 ± 3 mg/dL CKD-Carn; p < 0.0001), PTH (mean 1,738 ± 1,233 pg/mL CKD-Carn; p < 0.0001), creatinine (mean 1 ± 0.3 mg/dL CKD-Carn; p < 0.0001), cortical bone thickness (mean 0.5 ± 0.1 mm CKD-Ctrl, 0.4 ± 0.1 mm CKD-Carn; p < 0.05). Treadmill running significantly improves maximal aerobic capacity when compared to CKD-Ctrl (mean 14 ± 2 min CKD-TM, 10 ± 2 min CKD-Ctrl; p < 0.01).
Carnitine supplementation worsened CKD progression, mineral metabolism biochemistries, and cortical porosity and did not have an impact on physical function. Individualized treadmill running improved maximal aerobic capacity but did not have an impact on CKD progression or bone properties. Future studies should seek to better understand carnitine doses in conditions of compromised renal function to prevent toxicity which may result from elevated carnitine levels and to optimize exercise prescriptions for musculoskeletal health.
慢性肾脏病(CKD)会对肌肉骨骼健康产生负面影响,导致活动能力下降和生活质量降低。在健康人群中,已有报道称肉毒碱补充剂和有氧运动可改善肌肉骨骼健康。然而,关于其在 CKD 中的有效性和安全性的结果尚无定论。我们假设肉毒碱补充剂和个体化跑步机运动可改善 CKD 患者的肌肉骨骼健康。
我们使用自发性进展性 CKD 大鼠模型(Cy/+ 大鼠)(n = 11-12/组):(1)Cy/+(CKD-Ctrl),(2)CKD-肉毒碱(CKD-Carn)和(3)CKD-跑步机(CKD-TM)。肉毒碱(250 mg/kg)每日注射 10 周。跑步机组大鼠每周 4 天在 5°斜坡上跑步,持续 10 周,从第 1 周的 30 分钟/天增加到第 2 周的 40 分钟/天,再增加到第 8 周的 50 分钟/天。在 32 周龄时,我们评估了整体心肺功能、肌肉功能、骨组织学和结构以及肾功能。数据采用单因素方差分析和 Tukey 多重比较检验进行分析。
通过生化方法证实了中重度 CKD,血尿素氮(均值 43 ± 5 mg/dL CKD-Ctrl)、磷(均值 8 ± 1 mg/dL CKD-Ctrl)、甲状旁腺激素(PTH;均值 625 ± 185 pg/mL CKD-Ctrl)和血清肌酐(均值 1.1 ± 0.2 mg/dL CKD-Ctrl)。肉毒碱使磷(均值 11 ± 3 mg/dL CKD-Carn;p < 0.0001)、PTH(均值 1738 ± 1233 pg/mL CKD-Carn;p < 0.0001)、肌酐(均值 1 ± 0.3 mg/dL CKD-Carn;p < 0.0001)、皮质骨厚度(均值 0.5 ± 0.1 mm CKD-Ctrl,0.4 ± 0.1 mm CKD-Carn;p < 0.05)恶化。与 CKD-Ctrl 相比,跑步机跑步可显著提高最大有氧能力(均值 14 ± 2 分钟 CKD-TM,10 ± 2 分钟 CKD-Ctrl;p < 0.01)。
肉毒碱补充剂加重了 CKD 进展、矿物质代谢生化指标以及皮质骨孔隙度,对身体功能没有影响。个体化跑步机运动可提高最大有氧能力,但对 CKD 进展或骨骼特性没有影响。未来的研究应致力于更好地了解肾功能受损情况下肉毒碱的剂量,以防止因肉毒碱水平升高而导致的毒性,并优化运动处方以改善肌肉骨骼健康。